Scarica l'app Stockscreener
74.22
1.53%
-1.15
Dopo l'orario di chiusura:
74.50
0.28
+0.38%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DXCM Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$75.37
Aprire:
$75.7
Volume 24 ore:
5.39M
Relative Volume:
1.00
Capitalizzazione di mercato:
$28.64B
Reddito:
$4.82B
Utile/perdita netta:
$930.40M
Rapporto P/E:
31.74
EPS:
2.3381
Flusso di cassa netto:
$1.43B
1 W Prestazione:
-3.13%
1M Prestazione:
+20.43%
6M Prestazione:
+12.92%
1 anno Prestazione:
-9.48%
Intervallo 1D:
$73.53
$75.70
Intervallo di 1 settimana:
$73.53
$78.91
Portata 52W:
$54.11
$89.98
Dexcom Inc Stock (DXCM) Company Profile
Nome
Dexcom Inc
Settore
Industria
Telefono
(858) 200-0200
Indirizzo
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
74.22 | 29.08B | 4.82B | 930.40M | 1.43B | 2.3381 |
ABT
Abbott Laboratories
|
88.67 | 153.59B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
307.94 | 119.69B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
80.38 | 102.97B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
46.76 | 69.72B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.28 | 49.01B | 6.30B | 1.07B | 1.09B | 1.8406 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-24 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2026-01-12 | Downgrade | Barclays | Equal Weight → Underweight |
| 2025-12-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | Iniziato | Evercore ISI | In-line |
| 2025-10-21 | Ripresa | Stifel | Buy |
| 2025-09-08 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-08-21 | Iniziato | Argus | Buy |
| 2025-06-16 | Iniziato | Truist | Buy |
| 2025-05-30 | Iniziato | Goldman | Buy |
| 2025-04-10 | Iniziato | Mizuho | Outperform |
| 2025-02-03 | Aggiornamento | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | Iniziato | Redburn Atlantic | Neutral |
| 2024-03-12 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-05-30 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-04-17 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2023-01-26 | Iniziato | Wolfe Research | Outperform |
| 2022-10-18 | Iniziato | Barclays | Equal Weight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-07-15 | Iniziato | Bernstein | Outperform |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-02-03 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2022-01-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-10-18 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-07-21 | Ripresa | Cowen | Outperform |
| 2021-05-28 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Overweight |
| 2021-01-06 | Aggiornamento | UBS | Neutral → Buy |
| 2020-10-02 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | Reiterato | Piper Sandler | Overweight |
| 2020-05-14 | Iniziato | Wells Fargo | Equal Weight |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-11-07 | Reiterato | Canaccord Genuity | Buy |
| 2019-11-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-10-23 | Iniziato | Stifel | Buy |
| 2018-11-28 | Iniziato | UBS | Neutral |
| 2018-10-19 | Aggiornamento | Goldman | Sell → Neutral |
| 2018-09-12 | Aggiornamento | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | Reiterato | Canaccord Genuity | Buy |
| 2018-07-02 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-05-11 | Iniziato | BofA/Merrill | Buy |
| 2018-05-03 | Reiterato | Canaccord Genuity | Buy |
| 2018-04-04 | Iniziato | Goldman | Sell |
| 2018-04-04 | Iniziato | Guggenheim | Neutral |
| 2018-03-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | Downgrade | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | Reiterato | Wedbush | Outperform |
Mostra tutto
Dexcom Inc Borsa (DXCM) Ultime notizie
[144] DEXCOM INC SEC Filing - Stock Titan
Michael Brown files sale notice — Michael Brown (NASDAQ: DXCM) seeks to sell 1,700 shares - Stock Titan
Dexcom Scores Pediatric Expansion For OTC Stelo Glucose Monitor - Benzinga
In a first, Dexcom’s OTC glucose sensor is cleared for kids - MedTech Dive
Redefining CGM for people with type 2 diabetes: Dexcom announces Dexcom Flex in Germany - MSN
DexCom’s quarterly earnings preview: What you need to know - MSN
Dexcom reports positive CONNECT data for non-insulin diabetes - MSN
DexCom (DXCM) Launches First Over-the-Counter Glucose Monitor fo - GuruFocus
Dexcom (DXCM) Launches First OTC Glucose Monitor for Children - GuruFocus
FDA clears first over-the-counter glucose monitor for children - marketscreener.com
DexCom Inc. stock outperforms competitors on strong trading day - MSN
Here's why you should retain DexCom stock in your portfolio - MSN
DexCom Expands Beyond CGMs With CONNECT Results AI Apps And Nutrisense Deal - Yahoo Finance
Lyell Wealth Management LP Cuts Holdings in DexCom, Inc. $DXCM - MarketBeat
Vestal Point Capital, LP's DexCom Inc(DXCM) Holding History - GuruFocus
A Watch on DexCom: Expanding Access and Innovation Drive the Next Chapter of CGM Leadership - Kalkine
3 Reasons Investors Love DexCom (DXCM) - Yahoo Finance
Pharmsource says it was unaware Dexcom sensors it bought were slated for destruction - Reuters
Goodman Advisory Group LLC Invests $1.29 Million in DexCom, Inc. $DXCM - MarketBeat
DexCom Says Diabetes Tech Issue Isn't Investor Fraud - Law360
TD Cowen Remains a Buy on Dexcom (DXCM) - The Globe and Mail
DexCom Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Dexcom Inc. stock (US2521311074): TD Cowen lifts target after strong Q1 momentum - AD HOC NEWS
TD Cowen raises DexCom stock price target to $95 on data - Investing.com UK
TD Cowen Adjusts Price Target on DexCom to $95 From $75, Maintains Buy Rating - marketscreener.com
DXCM News | DEXCOM INC (NASDAQ:DXCM) - ChartMill
Motley Fool Asset Management LLC Raises Stake in DexCom, Inc. $DXCM - MarketBeat
DexCom Inc (DXCM)'s Winning Formula: Financial Metrics and Compe - GuruFocus
Is DexCom stock underperforming the Dow? - MSN
DXCM to launch Dexcom Flex CGM system for type 2 diabetes in Germany - MSN
Dexcom stock (US2521311074): Mizuho lifts target after diabetes study - AD HOC NEWS
Pumps, patches and fixes at the ADA - BioWorld News
Dexcom bolsters evidence for glucose sensors for Type 2 diabetes - MedTech Dive
Devon Energy Corp stock (US2521311074): Dividend, oil price moves and what matters for investors - AD HOC NEWS
Mizuho raises Dexcom stock price target to $85 on diabetes study - Investing.com
Raymond James Adjusts Price Target on DexCom to $91 From $81, Maintains Strong Buy Rating - marketscreener.com
DexCom Inc (DXCM) Stock Up 5.2% and Still Undervalued -- GF Scor - GuruFocus
Clinical Wins Boost Dexcom Growth Story In Type 2 DiabetesDexCom (NASDAQ:DXCM) - Benzinga
DexCom, Inc. (DXCM) latest stock news and headlines - Yahoo Finance Singapore
DexCom Reports Positive CONNECT Data for Non-Insulin Diabetes - TradingView
DexCom jumps as new ADA trial data boosts optimism for broader CGM adoption - Quiver Quantitative
Why is DexCom stock surging today? By Investing.com - Investing.com Canada
Mizuho Securities Adjusts DexCom Price Target to $85 From $75, Maintains Outperform Rating - marketscreener.com
DexCom, Inc. (DXCM): Investor Outlook Reveals 13.92% Potential Upside In Continuous Glucose Monitoring Market - DirectorsTalk Interviews
Fjarde AP Fonden Fourth Swedish National Pension Fund Has $7.30 Million Holdings in DexCom, Inc. $DXCM - MarketBeat
DexCom (DXCM) Reports Positive Trial Results for Glucose Control in Type 2 Diabetes - GuruFocus
Is It Time To Reassess DexCom (DXCM) After Recent Glucose Monitoring Headlines? - Sahm
World Investment Advisors Buys 16,749 Shares of DexCom, Inc. $DXCM - MarketBeat
Los Angeles Capital Management LLC Raises Holdings in DexCom, Inc. $DXCM - MarketBeat
DexCom, Inc. $DXCM Position Boosted by ING Groep NV - MarketBeat
PBU The Pension Fund of Early Childhood & Youth Educators Invests $3.19 Million in DexCom, Inc. $DXCM - MarketBeat
Dexcom Inc Azioni (DXCM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.64%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):